[中报]贝泰妮(300957):云南贝泰妮生物科技集团股份有限公司2024年半年度报告_英文版
|
时间：2024年08月28日 04:51:51 中财网 |
|
原标题:贝泰妮:云南贝泰妮生物科技集团股份有限公司2024年半年度报告_英文版
Yunnan Botanee Bio-Technology Group Co. LTD Section I Important Notice, Table of Contents, and Definitions Our Board of Directors, Board of Supervisors, directors, supervisors, and senior managers guarantee that this semi-annual report is true, accurate and complete without falsehoods, misleading statements or major omissions, and undertake individual and joint legal liabilities arising therefrom.
Our Chairman and President Guo Zhenyu, Chief Financial Officer (CFO) Wang Long, and Head of Accounting Department Liu Zhaofeng hereby declare that the financial report herein is true, accurate, and complete.
All directors of Botanee have attended the board meeting for deliberating on this semi-annual report.
Forward-looking statements herein on Botanee’s future prospects, business plans, etc. do not constitute substantial commitments to investors. Investors are advised to read carefully such information, and watch investment risks. Investors and related parties should maintain adequate risk awareness, and understand the differences between plans, forecasts, and commitments.
We have described in detail possible risks in our operations in “10. Risks and Countermeasures of Botanee” of “Section III Discussion and Analysis by the Management” of this report. Investors are kindly requested to pay attention to these sections.
The Company shall comply with the disclosure requirements for "Retail Industry" and “Chemical Industry-related Business” as stated in the Self-regulatory Guidelines for Listed Companies of Shenzhen Stock Exchange No. 3 - Industry Information Disclosure, and the disclosure requirements for “E-commerce Business” as stated in the Self-regulatory Guidelines for Listed Companies of Shenzhen Stock Exchange No. 4 - GEM Industry Information Disclosure.
We plan to not pay cash dividend, grant bonus shares and share issuance by transferring capital reserve.
Table of Contents
Section I Important Notice, Table of Contents, and Definitions ................................................................ 2
Section II Company Profile and Key Financial Indicators ....................................................................... 10
Section III Discussion and Analysis by the Management ......................................................................... 13
Section IV Corporate Governance ......................................................................................................... 49
Section V Environmental and Social Responsibility ................................................................................ 53
Section VI Significant Events ............................................................................................................... 57
Section VII Changes in Shares and Information about Shareholders......................................................... 65
Section VIII Preferred Shares................................................................................................................ 70
Section IX Bonds ................................................................................................................................. 71
Section X Financial Report ................................................................................................................... 72
Documents Available for Inspection
i. The original of our 2024 Semi-annual Report signed by the Company’s legal representative Mr. Guo Zhenyu.
ii. The financial statements signed and sealed by the Company’s legal representative Mr. Guo Zhenyu, CFO Mr. Wang Long, and Head
of Accounting Department Mr. Liu Zhaofeng, the person in charge of the accounting firm (Accounting Supervisor).
iii. The original of all our documents and announcements that have been publicly disclosed during the Reporting Period.
iv. Other relevant information.
The above documents are kept at our Board Secretary’s Office.
Definitions
| Term | Refers to | Definition |
| CSRC | Refers to | China Securities Regulatory Commission |
| SZSE | Refers to | Shenzhen Stock Exchange |
| The Company/Botanee | Refers to | Yunnan Botanee Bio-Technology Group Co. LTD |
| Botanee Co., Ltd. | Refers to | Kunming Botanee Bio-Technology Co., Ltd., the predecessor of Botanee |
| Shanghai Botanee | Refers to | Shanghai Botanee Bio-Technology Co., Ltd., a wholly-owned subsidiary of
Botanee |
| Beixiaoni (Shanghai) | Refers to | Beixiaoni (Shanghai) Technology Co., Ltd., a wholly-owned subsidiary of
Shanghai Botanee |
| Yanyao Medical Management | Refers to | Yanyao (Shanghai) Medical Management Co., Ltd., a wholly-owned
subsidiary of Shanghai Botanee |
| Yanyao Medical Beauty Clinic | Refers to | Shanghai Yanyao Medical Beauty Clinic Co., Ltd., a wholly-owned subsidiary
of Yanyao Medical Management |
| Botanee (Xiamen) | Refers to | Botanee (Xiamen) Technology Co., Ltd., a wholly-owned subsidiary of
Shanghai Botanee |
| Botanee (Hangzhou) | Refers to | Botanee (Hangzhou) Technology Co., Ltd., a wholly-owned subsidiary of
Shanghai Botanee |
| Botanee (Hainan) | Refers to | Botanee (Hainan) E-commerce Co., Ltd., a wholly-owned subsidiary of
Shanghai Botanee |
| Chengdu Botanee | Refers to | Chengdu Botanee Enterprise Management Co., Ltd., a wholly-owned
subsidiary of Botanee |
| Sichuan Botanee | Refers to | Sichuan Botanee Bio-Technology Co., Ltd., a holding subsidiary of Chengdu
Botanee |
| Wuhan Botanee | Refers to | Wuhan Botanee Bio-Technology Co., Ltd., a wholly-owned subsidiary of
Botanee |
| Kunming Botanee Sales | Refers to | Kunming Botanee Bio-Technology Sales Co., Ltd., a wholly-owned subsidiary
of Botanee |
| Kunming Yunzhuang | Refers to | Kunming Yunzhuang Biotechnology Co., Ltd., a wholly-owned subsidiary of
Botanee |
| Kunming Winona | Refers to | Kunming Winona Skincare Co., Ltd., a holding subsidiary of Kunming
Yunzhuang |
| Qiumei Technology (Shanghai) | Refers to | Qiumei Technology (Shanghai) Co., Ltd., a wholly-owned subsidiary of
Shanghai Botanee |
| Qiumei Technology (Kunming) | Refers to | Qiumei Technology (Kunming) Co., Ltd., a wholly-owned subsidiary of
Botanee |
| Shanghai Botanee Technology | Refers to | Shanghai Botanee Health Technology Co., Ltd., a wholly-owned subsidiary of
Botanee |
| Shanghai Jiyan Biomedical | Refers to | Shanghai Jiyan Biomedical Development Co., Ltd., a wholly-owned
subsidiary of Shanghai Botanee Technology |
| Botanee (Shanghai) Supply Chain | Refers to | Botanee (Shanghai) Supply Chain Management Co., Ltd., a wholly-owned
subsidiary of Shanghai Botanee Technology |
| Botanee (Kunming) Trading | Refers to | Botanee (Kunming) Trading Co., Ltd., a wholly-owned subsidiary of Botanee |
| Yunnan Yunke | Refers to | Yunnan Yunke Specialty Plant Extraction Laboratory Co., Ltd., a wholly-
owned subsidiary of Botanee |
| Shanghai Yibeini | Refers to | Shanghai Yibeini Health Technology Co., Ltd., a wholly-owned subsidiary of
Botanee |
| Aoxmed (Shanghai) | Refers to | Aoxmed (Shanghai) Biotechnology Co., Ltd., a holding subsidiary of
Shanghai Yibeini |
| Clinmate (Shanghai) | Refers to | Clinmate (Shanghai) Biotechnology Co., Ltd., a wholly-owned subsidiary of
Botanee |
| Hainan Botanee Investment | Refers to | Hainan Botanee Investment Co., Ltd., a wholly-owned subsidiary of Botanee |
| Term | Refers to | Definition |
| Yunnan Weijia | Refers to | Yunnan Weijia Biotechnology Co., Ltd., a holding subsidiary of Botanee |
| Sichuan Huifu Hospital
Management | Refers to | Sichuan Huifu Hospital Management Co., Ltd., a wholly-owned subsidiary of
Chengdu Botanee |
| Chengdu Huifu Internet Hospital | Refers to | Chengdu Wuhou Huifu Internet Hospital Co., Ltd., a wholly-owned subsidiary
of Sichuan Huifu Hospital Management |
| Chengdu Huifu Outpatient Clinic | Refers to | Chengdu Wuhou Yiduo Huifu Outpatient Clinic Co., Ltd., a wholly-owned
subsidiary of Sichuan Huifu Hospital Management |
| Shanghai Haimoni | Refers to | Shanghai Haimoni Biotechnology Co., Ltd., a wholly-owned subsidiary of
Kunming Yunzhuang |
| Xiamen Chonglou | Refers to | Xiamen Chonglou Private Equity Fund Management Co., Ltd., a wholly-
owned subsidiary of Botanee |
| Nibei (Shanghai) Technology | Refers to | Nibei (Shanghai) Technology Co., Ltd., a wholly-owned subsidiary of
Shanghai Yibeini |
| Kunming Ansute | Refers to | Kunming Ansute Biotechnology Co., Ltd., a wholly-owned subsidiary of
Shanghai Haimoni |
| Hangzhou Ansute | Refers to | Hangzhou Ansute Biotechnology Co., Ltd., a wholly-owned subsidiary of
Shanghai Haimoni |
| Shanghai Beforteen | Refers to | Shanghai Beforteen Technology Co., Ltd., a wholly-owned subsidiary of
Shanghai Yibeini |
| Sichuan Beforteen Enterprise | Refers to | Sichuan Beforteen Enterprise Management Co., Ltd., a wholly-owned
subsidiary of Chengdu Botanee |
| Chengdu Beforteen Internet
Hospital | Refers to | Chengdu Wuhou Beforteen Internet Hospital Co., Ltd., a wholly-owned
subsidiary of Sichuan Beforteen Enterprise |
| Chengdu Beifu Outpatient Clinic | Refers to | Chengdu Wuhou Beifu Comprehensive Outpatient Clinic Co., Ltd., a wholly-
owned subsidiary of Sichuan Beforteen Enterprise |
| Yunnan Botanee Technology | Refers to | Yunnan Botanee Health Technology Co., Ltd., a wholly-owned subsidiary of
Botanee |
| Huzhou Botanee | Refers to | Huzhou Botanee Biotechnology Co., Ltd., a wholly-owned subsidiary of
Shanghai Botanee Technology |
| Shangri-La Yunke | Refers to | Shangri-La Yunke Specialty Chinese Medicinal Materials Planting Co., Ltd.,
a wholly-owned subsidiary of Yunnan Yunke |
| Nuoweitai (Kunming) | Refers to | Nuoweitai (Kunming) Biotechnology Co., Ltd., a holding subsidiary of
Shanghai Yibeini |
| Clinmate (Kunming) | Refers to | Clinmate (Kunming) Biotechnology Co., Ltd., a wholly-owned subsidiary of
Clinmate (Shanghai) |
| Hunan Botanee | Refers to | Hunan Botanee Biotechnology Co., Ltd., a wholly-owned subsidiary of
Shanghai Botanee Technology |
| Hunan Botanee Medical Equipment | Refers to | Hunan Botanee Medical Equipment Co., Ltd., a wholly-owned subsidiary of
Hunan Botanee |
| Hunan Botanee Technology | Refers to | Hunan Botanee Health Technology Co., Ltd., a wholly-owned subsidiary of
Hunan Botanee |
| Yuejiang Investment | Refers to | ME (Guangzhou) Investment Co., Ltd., a wholly-owned subsidiary of Hainan
Botanee Investment |
| Yunnan Kelaiyimei | Refers to | Yunnan Kelaiyimei Health Management Co., Ltd., a wholly-owned subsidiary
of Clinmate (Shanghai) |
| Beijing Yibeini | Refers to | Beijing Yibeini Health Technology Co., Ltd., a wholly-owned subsidiary of
Kunming Botanee Sales |
| Beibeini (Shanghai) | Refers to | Beibeini (Shanghai) Technology Co., Ltd., a wholly-owned subsidiary of
Shanghai Botanee |
| Hangzhou Meixi | Refers to | Hangzhou Meixi Aesthetics Biotechnology Management Co., Ltd., a associate
invested by Hainan Botanee Investment |
| Shenzhen Nature | Refers to | Shenzhen Nature Technology Co., Ltd., a associate invested by Hainan
Botanee Investment |
| Beijing Huanfang Shidai | Refers to | Beijing Huanfang Shidai Information Technology Co., Ltd., a associate
invested by Hainan Botanee Investment |
| Term | Refers to | Definition |
| Yizheng (Suzhou) Biotech | Refers to | Yizheng (Suzhou) Biotechnology Co., Ltd., a associate invested by Shanghai
Botanee |
| Hunan Miaomiao Clinic | Refers to | Hunan Miaomiao Kelaiyimei Medical Beauty Clinic Co., Ltd., a associate
invested by Clinmate (Shanghai) |
| WEMT Medical | Refers to | WEMT Medical Technology (Wuxi) Co., Ltd., a associate invested by Hainan
Botanee Investment |
| Shanghai Weimu Medical | Refers to | Shanghai Weimu Medical Technology Co., Ltd., a associate invested by
Hainan Botanee Investment |
| Shenzhen Dieckman Biotechnology | Refers to | Shenzhen Dieckman Biotechnology Co., Ltd., a associate invested by Hainan
Botanee Investment |
| Metis Information Technology
(Guangzhou) | Refers to | Metis Information Technology (Guangzhou) Co., Ltd., a associate invested by
Hainan Botanee Investment |
| Hubei Yisen Clinic | Refers to | Hubei Kelaiyimei Yisen Clinic Co., Ltd., a associate invested by Clinmate
(Shanghai) |
| Nuona Technology | Refers to | Kunming Nuona Technology Co., Ltd., a controlling shareholder of the
Company |
| Sequoia Juye | Refers to | Tianjin Sequoia Juye Equity Investment Partnership (Limited Partnership), a
shareholder of Botanee |
| Zhenli Consulting | Refers to | Xiamen Zhenli Consulting Co., Ltd., a shareholder of Botanee |
| Yunnan Haqisheng | Refers to | Yunnan Haqisheng Enterprise Management Co., Ltd., a shareholder of
Botanee |
| Company Law | Refers to | Company Law of the People’s Republic of China |
| Securities Law | Refers to | Securities Law of the People’s Republic of China |
| KOL | Refers to | Key opinion leader, which usually refers to a person who has more access to
product information, is trusted by his/her audience, and can influence their
purchase |
| KOC | Refers to | Key opinion consumer, a consumer who can influence his/her friends and fans
to buy things |
| 618 | Refers to | The online shopping day that falls on June 18 every year, originated from
large-scale promotion activities created by JD.com on June 18, 2010 |
| Double 11 | Refers to | The online retail festival that takes place on November 11 every year,
originated from the large promotion created by Taobao Mall (now Tmall) on
November 11, 2009 |
| Cosmetics | Refers to | Chemical industrial products or fine chemical products applied by smearing,
spraying, or other similar means to any part of the surface of human body, such
as skin, hair, fingernails, toenails, lips, and teeth, for the purpose of cleaning,
taking care of, beautifying, modifying or altering the appearance, or for
modifying body odor to maintaining human body in good condition |
| Skincare products | Refers to | Cosmetics designed to protect or take care of the skin, and enhance its
elasticity and vitality |
| Dermatological level/functional
skincare products | Refers to | Skin care products with a mild and scientific formula suitable for sensitive skin
and other skin conditions which emphasizes safety and professionalism, as
defined by Euromonitor on dermocosmetics |
| Cosmetics industry | Refers to | The industry that covers infant and children products, bath products,
cosmetics, deodorant antiperspirants, hair removers, perfumes, hair care
products, men’s care products, oral care products, skincare products, sunscreen
products, etc., as defined by Euromonitor on beauty and personal care |
| Medical devices | Refers to | Instruments, equipment, appliances, in vitro diagnostic reagents and
calibrators, materials, and other similar or related articles used directly or
indirectly on human body. The medical devices manufactured and used by us
mainly include hyaluronic acid-based biofilms and hyaluronic acid-based
dressings used for the protection and care of barrier damaged skin after
minimally invasive procedures |
| E-commerce | Refers to | A new type of business operating model that enables online shopping by |
| Term | Refers to | Definition |
| | | consumers, online transactions between merchants, and online electronic
payments, as well as various business activities, transactions, financial
activities and related integrated services amidst a wide range of commercial
trade activities around the world, based on browser/server applications in an
open network environment on the Internet, where buyers and sellers conduct
various commercial activities without meeting each other |
| Online sales/online channel sales | Refers to | Product sales through e-commerce channels (telephone shopping, and TV
shopping included) |
| OMO sales/OMO channel sales | Refers to | Short for "Online-Merge-Offline", which adopts a new retail model that
combines online and offline methods for product sales by emphasizing user
experience and satisfying consumers' purchasing and social sharing needs. |
| Offline sales/offline channel sales | Refers to | Product sales through traditional sales channels (including department stores,
hypermarkets, cosmetic specialty stores, self-operated stores, pharmacies, etc.) |
| Registrant or filer of cosmetics | Refers to | Registrant who has obtained the special cosmetics registration certificate or
filer who has passed the filing of cosmetics. Registrants or filers are required
to fulfill the obligations of product registration and filing, launch the product
in the market in their name, are responsible for the quality, safety and efficacy
claims throughout the whole life cycle of the product, and manage the quality
and safety of the registered or filed cosmetics from research and development,
production (including but not limited to self-production or commissioned
manufacturing) to operation. |
| Registered or filed products | Refers to | Products that have been granted a special cosmetics registration certificate by
Botanee as a cosmetic registrant or filer, or that have passed the cosmetic filing |
| Commissioned manufacturing | Refers to | A manufacturing mode in which the client provides the commissioned with
product formula, raw and auxiliary materials, and packaging materials, and
sends an internal control team to guide and supervise the commissioned to
manufacture products in accordance with required process |
| CNY | Refers to | China’s statutory currency |
| The end of the Reporting Period | Refers to | June 30, 2024 |
| The beginning of the Reporting
Period | Refers to | January 1, 2024 |
| The end of previous/ last year | Refers to | December 31, 2023 |
| The Reporting Period | Refers to | From January 1, 2024 to June 30, 2024 |
| Same period of previous/last year | Refers to | From January 1, 2023 to June 30, 2023 |
Section II Company Profile and Key Financial Indicators
I. Company profile
| Stock name | Botanee | Stock code | 300957 |
| Stock exchange on which shares are
listed | Shenzhen Stock Exchange | | |
| Company name (in Chinese) | 云南贝泰妮生物科技集团股份有限公司 | | |
| Company name for short (in Chinese) | 贝泰妮 | | |
| Company name (in English) | Yunnan Botanee Bio-Technology Group Co. LTD | | |
| Company name for short (in English) | BTN | | |
| Legal representative | Guo Zhenyu | | |
II. Contact information
| | Board Secretary | Securities Representative |
| Name | Wang Long | Xu Ling |
| Address | No. 53, Keyi Road, High-tech
Development Zone, Kunming City,
Yunnan Province | No. 53, Keyi Road, High-tech
Development Zone, Kunming City,
Yunnan Province |
| Tel. | 0871-6801 3210 | 0871-6801 3210 |
| Fax | 0871-6801 3210 | 0871-6801 3210 |
| Email | [email protected] | [email protected] |
III. Other information
1. Contact information
Whether our registered address, office address and postal code, website and e-mail address have changed during the Reporting Period
or not
□ Applicable ? N/A
Our registered address, office address and postal code, website and e-mail address didn't change during the Reporting Period For details,
please refer to the 2023 Annual Report of Yunnan Botanee Bio-Technology Group Co. LTD (announcement No.: 2024-011) disclosed
by CNINFO (http://www.cninfo.com.cn).
2. Information disclosure and place for keeping documents available for inspection Whether information disclosure and place for keeping documents available for inspection have changed during the Reporting Period
or not
□ Applicable ? N/A
The name and address of the stock exchange website and media where we disclose our semi-annual report and the place for keeping
the semi-annual report available for inspection didn't change during the Reporting Period. For details, please refer to the 2023 Annual
Report of Yunnan Botanee Bio-Technology Group Co. LTD (announcement No.: 2024-011) disclosed by CNINFO
(http://www.cninfo.com.cn).
3. Changes in registration
Whether our registration has changed during the Reporting Period □ Applicable ? N/A
Our registration didn't change during the Reporting Period For details, please refer to the 2023 Annual Report of Yunnan Botanee Bio-
Technology Group Co. LTD (announcement No.: 2024-011) disclosed by CNINFO (http://www.cninfo.com.cn).
IV. Key accounting data and financial indicators
Whether we retrospectively adjusted or restated accounting data for previous years or not: □Yes ?No
| | Current Reporting
Period | Same Period of
Previous Year | Change over the
Same Period of
Previous Year |
| Operating revenue (CNY) | 2,804,672,799.97 | 2,367,742,613.94 | 18.45% |
| Net profit attributable to our shareholders (CNY) | 483,768,021.72 | 450,012,214.05 | 7.50% |
| Net profit attributable to our shareholders after deducting non-
recurring gains and losses (CNY) | 419,593,813.84 | 373,682,873.48 | 12.29% |
| Net cash flows from our operating activities (CNY) | 141,202,986.52 | 284,985,036.70 | -50.45% |
| Basic earnings per share (CNY/share) | 1.15 | 1.06 | 8.49% |
| Diluted earnings per share (CNY/share) | 1.15 | 1.06 | 8.49% |
| Weighted average return on net assets | 7.98% | 7.79% | Up by 0.19
percentage points |
| | End of the Current
Reporting Period | End of the
Previous Year | Change over the
End of the
Previous Year |
| Total assets (CNY) | 7,736,105,425.38 | 7,506,930,342.79 | 3.05% |
| Net assets attributable to our shareholders (CNY) | 5,970,813,515.54 | 5,860,994,371.02 | 1.87% |
Whether our share capital has changed from the end of the Reporting Period to the date disclosing this semi-annual report due to
issuance of new shares, additional issuance, allotment of shares, exercise of equity incentive, repurchase, etc., and whether the amount
of owners’ equity has been affected or not:
?Yes □No
| Dividends for preferred shares that have been paid | |
| Interest paid on perpetual bonds (CNY) | |
| Fully diluted earnings per share calculated based on the latest
share capital (CNY/share) | 1.1420 |
V. Differences in accounting data under Chinese and overseas accounting standards 1. Differences in net profit and net assets disclosed in our financial report prepared under the Chinese
accounting standards (CAS) and the international financial reporting standards (IFRS) □ Applicable ? N/A
2. Differences in net profit and net assets disclosed in our financial report prepared under CAS and overseas
accounting standards
□ Applicable ? N/A
VI. Item and amount of non-recurring gains and losses
? Applicable □ N/A
Unit: CNY
| Item | Amount | Note |
| Gains and losses from disposal of non-current assets (including the write-off of assets
impairment on provision) | -1,392,988.30 | |
| Government grants included in current profits and losses (except for government grants
that are closely related to our normal business operations, meet national policies and
regulations, are enjoyed in accordance with established standards, and have a lasting
impact on our gains and losses) | 42,466,126.97 | Government grants
included in “other
income” |
| Profit or loss arising from changes in fair value arising from the holding of financial
assets and financial liabilities by non-financial enterprises, and gains and losses arising
from the disposal of financial assets and financial liabilities in addition to effective
hedging business related to our normal business operations | 20,709,760.81 | Profit or loss arising
from changes in fair
value of entrusted
financial management
of cash management |
| Gains and losses from assets invested or managed by the entrusted | 28,489,104.21 | Investment income
generated by the
maturity of entrusted
financial management
of cash management |
| Other non-operating income and expenses other than the above | -7,935,493.09 | Public welfare
donations included in
“non-operating
expenses” |
| Minus: the Company’s income tax | 17,229,393.62 | |
| Minority shareholders’ interests (after tax) | 932,909.10 | |
| Total | 64,174,207.88 | |
Particulars about other items that meet the definition of non-recurring gains and losses: □ Applicable ? N/A
Explain the reasons if we identified an item as recurring gain/loss which is enumerated as non-recurring gains and losses in the
Explanatory Announcement on Information Disclosure by Companies Offering Securities to the Public No. 1: Non-recurring Profit
and Loss:
□ Applicable ? N/A
Section III Discussion and Analysis by the Management
Disclosure requirements for the “retail industry” as stated in the Self-regulatory Guidelines for Listed Companies of Shenzhen Stock
Exchange No. 3 - Industry Information Disclosure;
Disclosure requirements for “Chemical Industry-related Business” as stated in the Self-regulatory Guidelines for Listed Companies of
Shenzhen Stock Exchange No. 3 - Industry Information Disclosure; and Disclosure requirements for “E-commerce Business” as stated in the Self-regulatory Guidelines for Listed Companies of Shenzhen
Stock Exchange No. 4 - GEM Industry Information Disclosure. I. Main business operations during the Reporting Period
1. Overview of the industry during the Reporting Period
Botanee operates in the daily chemical product manufacturing industry, which is classified as “Manufacture of Chemical Raw Materials
and Chemical Products” (C26) in the Industry Classification Guidelines for Listed Companies issued by the China Association for
Public Companies. According to the Industrial Classification for National Economic Activities (GB/T4754-2017), Botanee falls under
the industry segment of cosmetics manufacturing (C2682) under daily chemical product manufacturing (C268).
According to data from the National Bureau of Statistics, the total retail sales of consumer goods in China during the Reporting Period
amounted to approximately CNY23.60 trillion, which represented a year-on-year increase of approximately 3.70%. Specifically, the
retail sales of cosmetics and personal care products by enterprises above designated size amounted to approximately CNY216.81 billion,
a year-on- year increase of approximately 1%. During the Reporting Period, the year-on-year growth rate of retail sales of cosmetics
and personal care products was lower than that of total retail sales of consumer goods, mainly due to the fact that the recovery of
domestic consumption capacity during the Reporting Period was yet to be further improved, and the cosmetics industry has shown
strong demand resilience.
2. Main business and products
Botanee focuses on the development of multiple brands, including core brand Winona as well as Winona Baby, AOXMED, Beforteen,
Za, and PURE&MILD. We specialize in providing professional and effective skincare products using pure natural plant-derived active
ingredients, with a particular emphasis on sensitive skin. As a specialized cosmetics manufacturer that integrates deeply with internet-
based sales channels, our mission is to “create China’s skin health ecosystem” by deeply understanding consumer needs, basing its
products on dermatological theories, and combining multidisciplinary technologies such as biology and botany to continuously conduct
product research and technological innovation. We strive to provide professional skincare products, medical devices and makeup
products that cater to different skin needs.
We have established a foundation through offline pharmaceutical channels and implemented an omnichannel strategy covering online
platforms. With an omnichannel system for new retail, we have successfully realized cross-sector marketing (OMO) leveraging the
internet and new technologies like artificial intelligence. This has facilitated mutual penetration between offline and online channels
and achieved extensive coverage of consumer groups, which makes Botanee a leading company in the internet+ greater health industry
in China. Additionally, we capitalize on the efficiency of the internet, the vast user traffic on mainstream e-commerce platforms, and
flexible new media marketing methods. With our strengths in e-commerce operations and high-quality products, we have successfully
seized the opportunities for rapid growth in the cosmetics industry driven by the “Chinese domestic products trend” in the past few
years.
Our main product categories include skincare products such as facial creams, toners, face masks, serums, lotions, as well as cosmetics
products such as sunscreens, powders, BB creams, and makeup removers. In addition to skincare and cosmetics, we are also engaged
in the research, development, production, and sales of medical devices related to skincare. This includes medical devices such as
hyaluronic acid repair biofilm and hyaluronic acid repair dressings used for the protection and care of damaged skin barriers after
minimally invasive procedures.
3. Main brand matrix
Winona Winona is a professional dermatological level skincare brand that is based on dermatological theories and supported by
scientific research and innovative technologies such as biology and botany. It targets sensitive skin, addresses the root causes,
repairs the skin barrier, and helps users achieve healthy and beautiful skin.
Winona Baby Inheriting the genetic essence of the parent brand Winona, Winona Baby is a professional dermatological level skincare
brand based on pediatric dermatology. It utilizes the abundant resources of Yunnan to extract plant essences, adhering to the
concept of “professional care for delicate baby skin” and dedicated to safeguarding the skin health of infants and young
children.
AOXMED AOXMED is committed to creating highly effective and safe professional beauty solutions and providing an exquisite
skincare experience. With cutting-edge scientific research and advanced formulation technology as its foundation, AOXMED
focuses on multidimensional skin rejuvenation, bringing professional anti-aging technologies that empower the skin with
youthful vitality.
Beforteen Beforteen is a professional acne treatment brand that utilizes big data on Chinese skin diseases as its research foundation. By
combining top medical research with AI deep learning, it has developed a unique integrated and precise acne solution.
Za Za focuses on the characteristics of Asian women’s skin and offers high-performance base cosmetics solutions that are multi-
functional and easy to use. It is an international light makeup brand that allows users to effortlessly enjoy their beautiful
daily life.
PURE&MILD With a 22-year brand history and designed specifically for Chinese women, PURE&MILD harnesses the power of technology
to enhance the benefits of plant extracts. It carefully selects rare plants and effective ingredients globally to help consumers
achieve youthful and vibrant skin changes.
4. Business model
(1) Main business sales models
During the Reporting Period, we adhered to an offline-based channel as the foundation and an online channel as the main driver,
utilizing in-depth private domain OMO (Online-Merge-Offline) approach to successfully promote an integrated omnichannel sales
model.
| | Sales Model | Description | Returns or Exchanges
Obligations and Risks in the
Sales Model | Revenue and Cost Recognition
Policies |
| Online
self-
operation | Self-
operation | Promote and sell products through self-
operated stores on major B2C platforms
such as Tmall, Douyin, Winona Online
Mall, or by guiding consumers through
offline promotions to make purchases on
our OMO platform called Winona
Counter Service Platform which is built
on Tencent’s ecosystem. | Based on the returns or
exchanges rules of each
platform, a generally accepted
policy is a 7-day or 14-day no-
reason return or exchange
policy. After the consumer
confirms receipt of the goods
by clicking “confirm receipt”
or when the platform's
specified receipt deadline is
reached and the receipt is
automatically confirmed, the
revenue is recognized, and the
costs are allocated. During the
Reporting Period, the
Company consistently
followed the returns or
exchanges policies of the
respective platforms. | Consumers place orders and
make payments online. After
the Company ships the goods,
consumers receive the
products and click to confirm
receipt, or when the
designated deadline for
receipt on the platform is
reached, the receipt is
automatically confirmed. At
that point, the revenue is
recognized, and the costs are
allocated. |
| Online
distribution | Distribution | Sign product purchase and sales
agreements with online distributors, who
independently sell products through their
own stores on major B2C platforms. | No returns or exchanges are
accepted unless there are
quality issues. During the
Reporting Period, the
Company consistently
followed the returns or | We deliver products to buyers
as agreed in the contract, and
after the buyers accept and
sign the Logistics Receipt, the
sales revenue is recognized
and costs are allocated. |
| | Sales Model | Description | Returns or Exchanges
Obligations and Risks in the
Sales Model | Revenue and Cost Recognition
Policies |
| | | | exchanges policies of the
respective platforms. | |
| | Consignment | Sign product consignment agreements
with major B2C platforms, and settlement
is based on the actual sales of products
and other agreed-upon methods on the
platforms, such as VIPShop, etc. | No returns or exchanges are
accepted unless there are
quality issues. During the
Reporting Period, the
Company consistently
followed the returns or
exchanges policies of the
respective platforms. | Botanee delivers products to
the consignees, and after the
consignees make sales to
external customers and issue
Consignment List to the
Company, the sales revenue is
recognized and costs are
allocated. |
| Offline
self-
operation | Self-
operation | Directly sell products to consumers
through physical self-operated stores,
utilizing the OMO model. | No returns or exchanges are
accepted unless there are
quality issues. During the
Reporting Period, the
Company consistently
followed the returns or
exchanges policies of the
respective platforms. | Consumers select the goods,
make on-site payments, and
collect the goods. After the
transaction is completed,
revenue is recognized, and
costs are allocated. |
| Offline
distribution | Distribution | Sign product purchase and sales
agreements with offline distributors, who
sell products through their offline sales
networks. | No returns or exchanges are
accepted unless there are
quality issues. During the
Reporting Period, the
Company consistently
followed the returns or
exchanges policies of the
respective platforms. | We deliver products to buyers
as agreed in the contract, and
after the buyers accept and
sign the Logistics Receipt, the
sales revenue is recognized
and costs are allocated. |
| | Consignment | Sign product consignment agreements
with consignment customers, who sell
products through their offline sales
networks. Settlement is based on the
actual sales of products and other agreed-
upon methods. | No returns or exchanges are
accepted unless there are
quality issues. During the
Reporting Period, the
Company consistently
followed the returns or
exchanges policies of the
respective platforms. | Botanee delivers products to
the consignees, and after the
consignees make sales to
external customers and issue
Consignment List to the
Company, the sales revenue is
recognized and costs are
allocated. |
(2) Procurement model （未完）
